Now that Keros Therapeutics Inc’s volume has hit 1.04 million, investors get a glimpse of its size.

On Tuesday, Keros Therapeutics Inc (NASDAQ: KROS) was -5.46% drop from the session before settling in for the closing price of $14.56. A 52-week range for KROS has been $9.12 – $72.37.

A company in the Healthcare sector has jumped its sales by 410.20% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 37.80%. With a float of $32.87 million, this company’s outstanding shares have now reached $40.55 million.

In an organization with 169 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 74.23%, operating margin of -5938.96%, and the pretax margin is -5269.1%.

Keros Therapeutics Inc (KROS) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Keros Therapeutics Inc stocks. The insider ownership of Keros Therapeutics Inc is 19.05%, while institutional ownership is 91.91%. The most recent insider transaction that took place on Apr 09 ’25, was worth 9,464,512. In this transaction 10% Owner of this company bought 934,258 shares at a rate of $10.13, taking the stock ownership to the 4,392,737 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 250,000 for $44.01, making the entire transaction worth $11,002,500. This insider now owns 119,522 shares in total.

Keros Therapeutics Inc (KROS) Performance Highlights and Predictions

According to the Wall Street analysts, stocks earnings will be around 37.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.82% during the next five years compared to -48.13% drop over the previous five years of trading.

Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators

You can see what Keros Therapeutics Inc (KROS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 21.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 157.41.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.01, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -4.30 in one year’s time.

Technical Analysis of Keros Therapeutics Inc (KROS)

Let’s dig in a bit further. During the last 5-days, its volume was 0.76 million. That was inferior than the volume of 1.34 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 56.49%. Additionally, its Average True Range was 0.64.

During the past 100 days, Keros Therapeutics Inc’s (KROS) raw stochastic average was set at 7.72%, which indicates a significant decrease from 43.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.31% in the past 14 days, which was lower than the 216.57% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $12.02, while its 200-day Moving Average is $34.55. However, in the short run, Keros Therapeutics Inc’s stock first resistance to watch stands at $14.34. Second resistance stands at $14.92. The third major resistance level sits at $15.34. If the price goes on to break the first support level at $13.34, it is likely to go to the next support level at $12.92. Assuming the price breaks the second support level, the third support level stands at $12.34.

Keros Therapeutics Inc (NASDAQ: KROS) Key Stats

There are 40,611K outstanding shares of the company, which has a market capitalization of 558.81 million. As of now, sales total 3,550 K while income totals -187,350 K. Its latest quarter income was 3,040 K while its last quarter net income were -46,030 K.